212Pb-DOTAMTATE
An alpha-particle version of neuroendocrine radioligand therapy that produced responses in over half of patients who had never had PRRT, with FDA Breakthrough designation.
Overview
ALPHAMEDIX-02 (Sanofi/Orano Med/RadioMedix, October 2025): met all primary endpoints; ORR 54.3% in PRRT-naive patients with ~70-75% progression-free at about 3 years, and durable disease control in PRRT-exposed patients (~83% progression-free at 18 months). Breakthrough Therapy designation 2024. Sanofi acquired global rights (2024); registrational strategy under discussion. Supply relies on Orano Med's 212Pb generators.
DOTAMTATE (SSTR2 agonist) chelating 212Pb, which decays via 212Bi to emit an alpha particle at the tumour cell. Connects to Somatostatin receptor 2.
- PSMA / SSTR-positive cell
1.212Pb-DOTAMTATE binds Somatostatin receptor 2 on the cancer cell or is taken up by it.
Deals
Deal map| Date | Deal | Type | Upfront | Total | Source |
|---|---|---|---|---|---|
| 2024-09-12 | RadioMedix to Sanofi AlphaMedix (lead-212 DOTAMTATE), targeted alpha therapy for neuroendocrine tumours | Licence | €100m | up to €220m in sales milestones plus tiered royalties | source |
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"212Pb-DOTAMTATE" OR ABSTRACT:"212Pb-DOTAMTATE" OR TITLE:"AlphaMedix" OR ABSTRACT:"AlphaMedix") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about 212Pb-DOTAMTATE, not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialACTION-1
Shares Beta PRRT → alpha PRRT, SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha, Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline, Pancreatic neuroendocrine tumours.
- IdeaSSTR antagonist radioligands to increase tumour dose
Shares SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha, Small intestinal neuroendocrine tumours, Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT).
- AgentActinium-225 DOTATATE
Shares SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha, Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline, Actinium-225 supply: thorium stocks, accelerators and radium targets, Pancreatic neuroendocrine tumours.
- TermPRRT (peptide receptor radionuclide therapy)
Shares Lead-212, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Somatostatin receptor 2.
- CompanyMolecular Targeting Technologies
Shares Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT).
- AgentLutetium-177 dotatate (radioligand equivalent)
Shares Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT).
- Agent177Lu-edotreotide
Shares Lead-212 VMT-alpha-NET, SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha, Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours.
- TrialCOMPETE
Shares Pancreatic neuroendocrine tumours, Small intestinal neuroendocrine tumours, Somatostatin receptor 2, Peptide receptor radionuclide therapy (PRRT).